Cutanos
Cutanos is a biotechnology company dedicated to developing next-generation vaccines and immunotherapies. They focus on targeted delivery systems to immune cells, particularly Langerhans cells, to enhance vaccine efficacy and safety. Their innovative LC-TDS technology aims to improve vaccine acceptance and accessibility worldwide, with a commitment to sustainability and health security.
Industries
Nr. of Employees
small (1-50)
Cutanos
Josef-Holaubek-Platz 2 (UZA II), 1090 Vienna, Austria
Products
Langerhans cell-targeted delivery platform (ligand-based nanoparticle delivery for skin administration)
A modular platform that functionalizes lipid-based nanoparticles or liposomes with small-molecule ligands to selectively deliver protein antigens or mRNA to Langerhans cells in skin, enabling minimally invasive administration via microneedles or microinjectors.
Langerhans cell-targeted delivery platform (ligand-based nanoparticle delivery for skin administration)
A modular platform that functionalizes lipid-based nanoparticles or liposomes with small-molecule ligands to selectively deliver protein antigens or mRNA to Langerhans cells in skin, enabling minimally invasive administration via microneedles or microinjectors.
Services
Collaborative projects with pharmaceutical partners and funders to apply cell-targeted delivery technology to vaccines and immunotherapies, including translational project support.
Preclinical assays and in vivo studies to evaluate antigen-specific immune responses following receptor-mediated delivery to skin immune cells.
Preparation and dissemination of peer-reviewed publications, conference presentations, and webinars on targeted antigen and nanoparticle delivery to immune cells in skin.
Collaborative projects with pharmaceutical partners and funders to apply cell-targeted delivery technology to vaccines and immunotherapies, including translational project support.
Preclinical assays and in vivo studies to evaluate antigen-specific immune responses following receptor-mediated delivery to skin immune cells.
Preparation and dissemination of peer-reviewed publications, conference presentations, and webinars on targeted antigen and nanoparticle delivery to immune cells in skin.
Expertise Areas
- Targeted vaccine delivery
- Langerhans cell and dendritic cell targeting
- mRNA vaccine formulation and stabilization
- Lipid nanoparticle and liposomal formulation
Key Technologies
- Glycomimetic ligand design for receptor targeting
- Lipid nanoparticles (LNPs)
- Liposomal delivery systems
- Microneedle-based skin delivery
News & Updates
Langerhans Cell-targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response. The study demonstrates specific delivery of protein antigens to dendritic cells, significantly enhancing immune response in vivo, and underscores the potential of LCs as an access point for next-generation vaccines and immunotherapies.
Cutanos GmbH was awarded first place in the BARDA VITAL Prize Challenge for innovative vaccine technology, validating their commitment to developing vaccine solutions that can make a real difference in the fight against infectious diseases.
Welcome Ramona Rîca and Litty Johnson, the latest additions to Cutanos' science team, bringing expertise in immunology and material science.
We welcome Klara Klein as Scientist and Project Lead, with expertise in immunology, to lead her own research project.
Ulrich Platte joins as CFO & CBO, bringing business development expertise to the team.
Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin. The study demonstrates targeted antigen delivery to immune cells, particularly dendritic cells, as a promising strategy to enhance vaccine efficacy.
Langerhans Cell-targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response. The study demonstrates specific delivery of protein antigens to dendritic cells, significantly enhancing immune response in vivo, and underscores the potential of LCs as an access point for next-generation vaccines and immunotherapies.
Cutanos GmbH was awarded first place in the BARDA VITAL Prize Challenge for innovative vaccine technology, validating their commitment to developing vaccine solutions that can make a real difference in the fight against infectious diseases.
Welcome Ramona Rîca and Litty Johnson, the latest additions to Cutanos' science team, bringing expertise in immunology and material science.
We welcome Klara Klein as Scientist and Project Lead, with expertise in immunology, to lead her own research project.
Ulrich Platte joins as CFO & CBO, bringing business development expertise to the team.
Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin. The study demonstrates targeted antigen delivery to immune cells, particularly dendritic cells, as a promising strategy to enhance vaccine efficacy.